Preclinical
Origami’s precision technology platform, Oricision™, is focused on diseases that affect the central nervous system rather than oncology.
BioAge Labs presented new data demonstrating how its drug candidate BGE-175 is uniquely poised to tackle age-related immune system decline that leads to disease progression.
The platform, called LOCOcyte™, is a cytokine delivery platform that is made of polymer-encapsulated human ARPE-19 cells that produce natural cytokines.
The identification of multiple genomic markers that are linked to specific mental health diseases is beginning to improve treatments and enable precision psychiatry.
Akari announced that votucalis has potential as a treatment for pain and itch associated with conditions such as atopic dermatitis, psoriasis and neuropathic pain.
Exo Therapeutics’ approach is not only different, it has revolutionary potential.
Diabetes-focused life sciences company Zucara Therapeutics released preclinical findings on a daily therapy to slow and prevent plummeting blood glucose levels in Type 1 diabetes patients.
Research Roundup for February 4
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The portfolio of STING inhibitors is designed to treat autoimmune and inflammatory diseases.
PRESS RELEASES